What's new?

Added 6 days ago Drug news

Data for Exparel results in high rates of early discharge and patient satisfaction for total knee or hip arthroplasty

Pacira Pharmaceuticals, Inc. announced new data showing that a patient-optimizing, opioid-sparing enhanced recovery after surgery (ERAS) pathway, which includes intraoperative...

Added 5 days ago Drug news

FDA approves Dupixent to treat adolescents with atopic dermatitis

The FDA has approved Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose...

Added 2 hours ago Drug news

OG 217SC filed with the FDA for type 2 diabetes

Novo Nordisk announced the submission of two New Drug Applications (NDAs) to the FDA for OG 217SC (oral semaglutide), the...

Added 2 hours ago Drug news

Ozempic filed with FDA for risk reduction in MACE

Novo Nordisk has filed a supplemental NDA (sNDA) with the FDA for once-weekly Ozempic (semaglutide) injection 0.5 mg or 1...

Added 2 hours ago Drug news

Phase III JAVELIN Ovarian PARP 100 study is discontinued

Merck KGaA and Pfizer Inc. have announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating...

Added 2 hours ago Drug news

FDA approves Zulresso to treat postpartum depression

Sage Therapeutics announced the FDA has approved Zulresso (brexanolone) injection for the treatment of postpartum depression (PPD). Zulresso is the...

Added 1 day ago Drug news

Phase IIIb ELIMINATE-AF study of Lixiana shows safety and efficacy in bleeding events

Daiichi Sankyo announced results from phase IIIb ELIMINATE-AF, a prospective, randomised, open label, blinded endpoint evaluation (PROBE) design study assessing...